Dermacyte® Liquid for Treatment of Cutaneous Ulcers and Wounds

ConditionsCutaneous Ulcer Diabetic Ulcer Surgical Wound Dehiscence Burns - Multiple Pressure Ulcers Mixed Ulcer Ischemic Ulcer

Trial statusAvailable

Trial phaseNot listed

Trial typeExpanded Access

Biological sexAll

Age18+

SponsorMerakris Therapeutics

About this trial

The objective of this study is to make Dermacyte Liquid available on an expanded access basis to treat cutaneous ulcers and wounds refractory to initial treatment or that do not have adequate alternative treatments. Minimal data will be collected to evaluate the efficacy and safety of Dermacyte Liquid.

Eligibility criteria

Qualifiers

Must be 18 years of age or older

Must have a cutaneous ulcer or wound refractory to initial treatment or does not have an adequate treatment alternative, as determined by the Investigator

Disqualifiers

Must not be pregnant or lactating

Must not have known malignancies

Must not be less than 18 years of age

Trial design

Treatments tested in this trial

MTX-001 (Dermacyte Liquid)

Treatment groups

No treatment groups listed

Sponsors and collaborators

Merakris Therapeutics

Lead sponsor

Source ClinicalTrials.gov